ESR1 and urogenital neoplasm: In particular, the androgen receptor (AR) and estrogen receptor (ER) signaling pathways have been shown to contribute to bladder tumorigenesis and cancer progression (3–13), which may explain some of the differences in male versus female bladder cancer.